ArticleScientific reports2026
Spectral residual augmented classical least squares for simultaneous green determination of cetirizine, fexofenadine and loratadine by UV spectrophotometry in pharmaceuticals and environmental samples.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Second-generation antihistamines-cetirizine, fexofenadine, and loratadine-require simultaneous determination methods for pharmaceutical quality control including cleaning validation and cross-contamination monitoring in multi-product manufacturing facilities, yet their severely overlapping UV spectra preclude direct spectrophotometric quantification. This study developed a novel, sustainable UV-spectrophotometric method employing spectral residual augmented classical least squares (SRACLS) chemometrics to mathematically resolve spectral overlap and enable simultaneous quantification. Calibration (25 mixtures, partial factorial design) and validation sets (20 mixtures, central composite design) spanned 4-12 µg/mL concentration ranges. Comparative evaluation revealed that SRACLS demonstrated superior performance versus concentration residual augmented classical least squares (CRACLS), achieving 40-70% lower prediction errors (RRMSEP: 1.745, 2.605, 1.736 versus 3.011, 3.960, 2.674) and tighter residual distributions (± 3-5 versus ± 5-6 units). Subsequently, ICH Q2(R2) validation confirmed excellent analytical performance: recoveries 98.06-101.95% across the full working range, intra-day precision ≤ 1.522% RSD, inter-day precision ≤ 1.986% RSD, LOD values of 0.379-0.560 µg/mL, LOQ values of 1.149-1.697 µg/mL, and robust selectivity against pharmaceutical excipients and environmental co-contaminants (96.05-103.38% recovery). Application to commercial tablets yielded results statistically equivalent to reported HPLC methods (t-test, F-test: p > 0.05), whereas analysis of tap water samples spiked at concentrations relevant to pharmaceutical manufacturing facility effluents following salting-out assisted liquid-liquid extraction achieved 95.43-103.85% recovery. Moreover, comprehensive sustainability assessment demonstrated excellent performance: MoGAPI 76, CaFRI 85, AGSA 70.83, BAGI 77.5, CACI 66, and AMRI 68, attributed to eliminated organic solvent consumption, minimal energy usage, low waste generation, and high throughput (> 30 samples/hour). Overall, this work represents the first SRACLS application to antihistamine analysis, providing a practical green alternative to chromatographic methods for pharmaceutical quality control and manufacturing effluent monitoring applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.